Rating Rationale
January 07, 2020 | Mumbai
Mahatma Gandhi University of Medical Sciences and Technology
'CRISIL BBB+/Stable/CRISIL A2' assigned to bank debt
 
Rating Action
Total Bank Loan Facilities Rated Rs.458 Crore
Long Term Rating CRISIL BBB+/Stable (Assigned)
Short Term Rating CRISIL A2 (Assigned)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has assigned its 'CRISIL BBB+/Stable/CRISIL A2' ratings to the bank facilities of Mahatma Gandhi University of Medical Sciences and Technology (MGUMT).
 
The ratings reflect the university's longstanding track record in medical college and hospital management, its healthy occupancy ratio of college seats and hospital beds, and strong operating efficiency. The rating also takes into consideration the support of its trustees and the management's healthy reputation and its large and improving scale of operations and profitability. These strengths are partially offset by risks related to project completion and approvals, adverse regulatory changes, and competition from government medical college.

Key Rating Drivers & Detailed Description
Strengths:
* Longstanding track record: MGUMT (earlier managed by Indian Education Trust) started operations in 2001 with a hospital and later on expanded to provide education in medicine. Over the years, the university has diversified into education and hospital services. In 2011, it was granted university position under Jaipur Ordinance, 2011 (Ordinance No. 4 of 2011) by the Governor, and since then, it has expanded even further and has built a healthy reputation in the market.
 
* Healthy occupancy of college and hospital: The university has reported 100% occupancy in all the departments in the last three years, thus driving healthy occupancy. Furthermore, the university provides hospital services. The hospital has 1,472 beds, including 90 super specialty beds, 151 intensive care units/critical care units (ICU/CCU) beds, 97 beds in deluxe/private rooms, and 250 beds in the semi-private ward. In fiscal 2019, the hospital reported occupancy of 82%, which improved from 80% the previous fiscal.
 
* Strong operating efficiency: The university has been operating at a healthy level due to full occupancy of the course and healthy occupancy in the hospital. This has resulted in earnings before interest, taxes, depreciation, and amortisation of 24.4% in fiscal 2019, improving from 18.9% in the previous fiscal. Return on capital employed was healthy at around 14% in fiscal 2019.
 
* Trustees' support and the management's healthy reputation: The trustees have been providing consistent support in shaping the quality of education provided at the university. They have taken care of the operations of the university and have implemented best practices from their decade-long experience in the education and hospital management. Furthermore, they have provided unsecured loans during the university's expansion phase.
 
* Large scale of operations and improving profitability: Scale of operations is large, indicated by revenue of Rs 294.58 crore in fiscal 2019 (Rs 232.38 crore the previous fiscal), improving from Rs 161.3 crore in fiscal 2016. This improvement is majorly triggered by growth in hospital and education income. With commencement of Medicinae Doctor (MD) ,Master of Surgery (MS), Doctorate of medicine (DM) courses in fiscal 2021, hospital beds (210 beds), additions of 100 seats to bachelor of medicine and bachelor of surgery (MBBS) course and various radiation blocks and other labs in fiscal 2022, receipts are expected to increase further. Currently, around 50% of the capital expenditure (capex) is completed, and the rest is expected to be completed on time.
 
Weaknesses:
* Project completion- and approval-related risk: The university has revised its third phase of expansion (Phase III) expenditure, which now comprises addition of 100 MBBS seats (unchanged), 44 MD/MS seats (from 42), 42 DM/ Magister Chirurgiae (M Ch) seats (from 21), 95 hostel beds (from 384), scrapping of 24 staff quarters, and 210 hospital beds (from 360). However, there is no change in additional medical facilities, which include a nuclear medicine and nuclear therapy unit, diagnostic laboratory medicine, medicine and paediatric surgery and paediatric radiology, and the Department of Transfusion Medicine/Blood Bank and Bone Marrow and Stem Cell Transplantation. This revision has reduced the capex from Rs 423 crore to Rs 252.85 crore. This revision in project is also expected to lead to reduction in the term loan for the project to Rs 164.25 crore (which was earlier estimated at Rs 278.39 crore). The university will draw term loan to the tune of only Rs 164.25 crore out of total sanction of Rs 278.39 (till September, 2019 Rs 82.52 crore has been utilised from such term loan) as articulated by management. Until September, 2019 the university incurred around 50% of the capex (Rs 123 crore) and is expected to complete the capex in phases in between fiscals 2021 and 2022. Furthermore, the university needs approval from various departments for the addition of university seats; this is in process. Therefore, time taken for the completion and approval of the project will remain a key rating sensitivity factor.
 
* Risk related to unfavourable regulatory changes: Establishment and operations of educational institutions are regulated by various governmental and quasi-governmental agencies, such as the University Grants Commission, All India Council for Technical Education, universities, state governments, Medical Council of India, and Indian Nursing Council. Each body has detailed procedures for granting permission to set up institutions, and approvals need to be renewed every three or five years. Also, the university needs to regularly invest in its workforce and infrastructure. Any non-compliance would result in cancellation of affiliation and license, leading to loss of reputation for the college and revenue for the trust. Also, risks related to any regulatory changes implemented by these bodies could have a disruptive effect on some private education institutions (such as changes in the student teacher ratio and increases in minimum infrastructure and fees control).
 
* Risk of competition from government medical college: Demand for government colleges is high because of lower fees charged by them. Due to the mismatch between demand and availability, private colleges have been able to cater to this space. However, in recent years, the government has started to acknowledge that there is a steep gap between demand for medical colleges and their availability and has started to act upon this. Government actions include relaxation of norms for private college and universities along with addition of government colleges. In 2019, the government gave the nod for setting up of 75 new medical colleges. Previously, the government extended permission for 58 medical colleges in phase I and another 24 in phase II; this led to addition of 15,700 MBBS seats across the country. Out of those approved in phase I, around 39 medical colleges are already operational. Therefore, addition of government colleges, where fees is substantially lower than private colleges, could attract prospective students away from private colleges.
Liquidity Adequate

Cash accrual is expected at Rs 61.4 crore, Rs 79 crore, and Rs 87 crore against debt obligation of Rs 28.01 crore, Rs 30.89 crore and Rs34 crore in fiscals 2020, 2021, and 2022, respectively. Further the repayment schedule is structured in such a way that large repayment obligation for the year falls due in the month of October, which is post receipt of fees from education department. The university is expected to have minimum debt service coverage ratio (DSCR) of 1.6 times over the next three years. DSCR has been calculated considering reduction in repayment obligation due to revision of capex and thereby expected reduction of debt for the project (phase III) to Rs 164.25 crore from Rs 278.39 crore as articulated by management. Utilisation of bank overdraft limit of Rs 35.97 crore averaged 87% over the 12 months through November 2019. Capex of around Rs 129 crore (around 50% of the current capex) is to be completed by October 2021. This project is funded by term loan of Rs 164.25 crore out of total cost of Rs 252.85 crore.

Outlook: Stable

CRISIL expects MGMT to continue to benefit from its healthy market position, strong occupancy level, and comfortable operating performance, supported by experienced management.

Rating Sensitivity factors
Upward factors
* Timely completion of capex along with stabilisation leading to improvement in cash accrual by 20% and reduction in term debt
* Efficient working capital management leading to increase in profitability margin and improvement in accrual, which could lead to build-up of liquid funds
 
Downward factors
* Delay in getting approval for new courses from the designated authority
* Any adverse regulatory changes impacting the performance of the university
* Fall in DSCR to below 1.5 times over the medium term

About the university
MGUMT is Jaipur-based private university and one of the largest private hospitals in Rajasthan, spread across 36 acres of land. It gained university status in 2011. It offers various medical, nursing, and dental courses and provides inpatient and outpatient healthcare services through aggregate capacity of 1,472 beds under Mahatma Gandhi Hospital. India Education Trust (IET) is the sponsoring body of MGUMT. Dr. M. L. Swarankar, Mrs. Meena Swarankar, Mr. R. R. Soni and Mrs. Neelam Soni are founders of IET.
Key Financial Indicators
Particulars Unit 2019 2018
Revenue Rs Crore 295.64 232.87
Profit After Tax Rs Crore 31.27 14.61
PAT Margin % 10.58 6.28
Adjusted Debt/Adjusted Networth Times 1.98 1.79
Interest coverage Times 2.47 2.25

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of Instrument Date of
Allotment
Coupon
Rate (%)
Maturity
Date
Issue Size
(Rs Crore)
Rating Assigned
with Outlook
NA Long Term Loan NA NA Sep-31 397.83 CRISIL BBB+/Stable
NA Bank Guarantee NA NA NA 24.2 CRISIL A2
NA Overdraft NA NA NA 35.97 CRISIL BBB+/Stable
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  433.80  CRISIL BBB+/Stable    --    --    --    --  -- 
Non Fund-based Bank Facilities  LT/ST  24.20  CRISIL A2    --    --    --    --  -- 
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Overdraft 35.97 CRISIL BBB+/Stable -- 0 --
Bank Guarantee 24.2 CRISIL A2 -- 0 --
Long Term Loan 397.83 CRISIL BBB+/Stable -- 0 --
Total 458 -- Total 0 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
CRISILs criteria for rating Education institutions
CRISILs Bank Loan Ratings
CRISILs Criteria for rating short term debt
The Rating Process

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Mohit Makhija
Director - CRISIL Ratings
CRISIL Limited
B:+91 124 672 2000
mohit.makhija@crisil.com


Jaya Mirpuri
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 20 4018 1926
jaya.mirpuri@crisil.com


Saurav Kumar Jha
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 33 4011 8222
Saurav.Jha@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL